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Abstract: Patients with chronic renal disease are at increased risk for the development of 
cardiovascular disease, which is the main cause of death in this growing population. Among 
the risk factors involved, hypertension and proteinuria are major contributors to kidney damage 
and, if not controlled, may eventually lead to the progression of renal failure and end-stage renal 
disease. Both proteinuria and hypertension can be primary pathologic events or can appear as 
complications of other disease processes. Initially, these two factors may operate separately but, 
as progression ensues, both processes generally combine, potentiating their effects and hastening 
renal damage. Therefore, strategies to reduce blood pressure and proteinuria are essential in 
order to slow the worsening of many nephropathies. Therapies that target the renin–angiotensin 
system offer particular benefit, as hypertension and proteinuria can be precisely reduced with 
angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers. However, with 
this intervention, plasma renin activity remains high, and although primary endpoints may be 
controlled, elevated renin concentration can contribute to cardiovascular damage. Aliskiren, a 
direct renin inhibitor, is the first example of a novel class of antihypertensive drugs with potent 
antiproteinuric effects, which, alone or combined, can contribute to delaying the progression 
of kidney disease.
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Introduction to blood pressure management  
and renoprotection
Hypertension and diabetes mellitus account for over 50% of cases of chronic kidney 
disease. High blood pressure itself is a major risk factor for the progression of renal 
disease, affecting approximately 30% of the adult population in Western countries.1 
As pointed out by Ritz2 in an editorial regarding the 2007 World Kidney Day, “High 
blood pressure, not necessarily the ‘disease’ hypertension according to current defini-
tions (JNC7), is a major killer …” If a subject presents a blood pressure of 140 mm 
Hg systolic, the risk of stroke or myocardial infarction is double that of someone with 
a blood pressure of 120 mm Hg systolic. However, with a systolic blood pressure of 
120–130 mm Hg, rather than 120 mm Hg or lower, the risk of end-stage renal disease 
is approximately 62% and rises to nearly 160% with a pressure of 130–140 mm Hg.3 
Therefore, an aggressive approach to blood pressure reduction is mandatory. However, 
it is estimated that only a small percentage of hypertensive patients have adequate blood 
pressure control. This situation can, in part, explain the growing number of cases of 
chronic renal failure. According to the recently published United States Renal Data 
System (USRDS) report, in the general population, 31% of hypertensives are unaware International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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of their diagnosis, 11% are aware but not treated, 24% are 
treated but uncontrolled, and only 34% of subjects are aware, 
treated, and well controlled. Surprisingly, in patients with 
chronic kidney failure stages 3–4 (glomerular filtration rate 
15–60 mL/min), 24% are unaware of being hypertensive, 
6% are aware but not treated, 50% are aware but poorly 
controlled, and only 20% have their blood pressure controlled 
(,130–180 mm Hg).4 In the same report, it is shown that 
91.4% of chronic kidney patients are hypertensive.5 This 
grim reality may partially explain why the adjusted rate of 
prevalent cases of end-stage renal disease in the US rose 1.9% 
in 2008 (the same rate growth as that seen in 2007) to 1699 
per million population. This rate is nearly 20% higher than 
that seen in 2000. The annual rate of increase has remained 
stable between 1.9% and 2.3% since 2003.6
Proteinuria is another relevant target, as it is a major risk 
factor for renal disease progression.7–9 Proteinuria can be due 
to primary glomerulopathies (focal and segmental glom-
erulonephritis, membranous nephropathy, minimal change 
disease, Berger’s disease, membranoproliferative glomerulo-
nephritis), which are the third most likely cause of end-stage 
renal disease in the adult population and an important cause of 
secondary hypertension, or to secondary glomerular damage 
as a result of primary hypertension, diabetes mellitus, reflux 
nephropathy, or other causes of renal disease. A coexistent 
diagnosis of hypertension and diabetes increases the risk of 
adverse cardiovascular and renal outcomes. This increased 
risk extends to a diastolic blood pressure of $83 mm Hg and 
a systolic blood pressure of $127 mm Hg.10,11 Reduction of 
proteinuria by .30% within the first 6–12 months of treat-
ment in patients with chronic kidney disease has been shown 
to predict long-term renal and cardiovascular outcomes.8,12 
Moreover, the management of albuminuria in normotensive 
or hypertensive patients with diabetes may slow progression 
of diabetic nephropathy.13 Microalbuminuria itself, an early 
marker of kidney vascular dysfunction, is a strong prognostic 
indicator of mortality and cardiovascular disease in hyper-
tension and diabetes mellitus.14,15 Therefore, one of the main 
goals to slow the progression of renal disease is an adequate 
and not unusually aggressive control of blood pressure and 
the reduction of proteinuria to its lowest possible level.
In this regard, the pharmacological manipulation of the 
renin–angiotensin–aldosterone system (RAAS) is an impor-
tant tool to employ, as renin, angiotensin II, and aldosterone 
are important molecules with hemodynamic and inflamma-
tory effects both systemically and locally, particularly in the 
kidney. Angiotensin-converting enzyme inhibitors (ACEIs) 
and angiotensin receptor blockers (ARBs) reduce proteinuria 
and blood pressure, either alone or combined.16 However, by 
attenuating feedback inhibition of renin release, ACEIs and 
ARBs effects lead to an increase in plasma renin concentration 
and activity, rendering incomplete inhibition of the RAAS 
system.17,18 Moreover, inhibition of ACE causes an increase 
in angiotensin I, which is then available for conversion to 
angiotensin II by ACE-independent pathways not blocked 
by ACEIs, namely cathepsins and tonins.19–21 Consequently, 
despite adequate blood pressure control, angiotensin II   levels 
increase aldosterone levels to certain degrees, rendering 
these inflammatory molecules free to play an active role in 
tissue remodeling and scarring. Henceforth, it is tempting 
and reasonable to assess the effects of a different pharma-
cologic strategy that blocks the RAAS upstream completely. 
Aliskiren is the first known representative of a new class of 
nonpeptide orally active renin inhibitors that block the RAAS 
at its rate-limiting step and induce a net reduction in plasma 
renin activity and angiotensin II and aldosterone levels.22–24 
Aliskiren has been assessed in recent years as an efficient 
antihypertensive drug, either alone or in combination with 
other drugs. Its antiproteinuric effects are notorious and may 
be independent of its antihypertensive effects, showing that 
aliskiren alone or combined can further decrease proteinuria 
and the risk of renal disease progression.25 This suggests that 
renin- or angiotensin-independent pathways may be involved 
in inflammatory processes of which proteinuria is a disease 
activity marker and that aliskiren can abrogate.
Review of aliskiren pharmacology, 
mode of action, pharmacokinetics, 
and effects on renal hemodynamics
The direct renin inhibitor aliskiren is an octanamide and a 
nonpeptide piperidine with high affinity and specificity for 
human renin,25 and it inhibits the enzyme renin by binding 
to its catalytic site, thus blocking the RAAS at its point of 
activation.26 In this respect, angiotensin I, angiotensin II, 
and aldosterone levels decrease, and their hemodynamic 
and inflammatory effects are abolished. Therefore, aliskiren 
impedes efferent arteriolar vasoconstriction and diminishes 
the glomerular filtration fraction, salt and water absorption, 
and angiotensin II-induced inflammatory actions. Moreover, 
it blocks renin and prorenin activity while renin and prorenin 
levels remain high.22,24,25
A recently discovered (pro)renin receptor activates 
when exposed to either renin or prorenin, the inactive form 
of renin.27 The (pro)renin receptor, in turn, enhances renin 
catalytic activity and allows prorenin to display catalytic 
activity without its proteolytic conversion to renin. This (pro)International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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renin receptor-induced prorenin activation could explain how 
prorenin exerts pathological effects in diabetic patients, where 
prorenin represents approximately 95% of total circulating 
renin.28 Interestingly, recent data have shown that renin and 
prorenin induce activation of the extracellular signal-regulated 
kinase (ERK) pathway, independent of angiotensin II. In this 
respect, aliskiren has no (pro)renin receptor-blocking action. 
Therefore, ACEIs, ARBs, and aliskiren all increase renin con-
centration, which could conceivably induce (pro)renin recep-
tor signaling without the involvement of angiotensin II, 
suggesting that blockade of the (pro)renin receptor might 
be an alternative or an adjunct to renin–angiotensin system 
inhibition, particularly in conditions with high renin and/or 
prorenin levels.28 High prorenin levels are closely associated 
with the severity of diabetic complications. In this respect, 
in diabetics, increased prorenin levels have been shown to 
be associated with microalbuminuria and with the develop-
ment of nephropathy.29,30 However, aliskiren still blocks the 
tissue renin–angiotensin system, because at the (pro)renin 
receptor level, activated prorenin can immediately be blocked 
by aliskiren. The result would be angiotensin II production 
not occurring.28 Interestingly, renin bound to the (pro)renin 
receptor presents much more enhanced catalytic activity 
than soluble renin.31 The cloning of a functional receptor 
for both renin and prorenin suggests that renin and prorenin 
may exert direct angiotensin II-independent tissue-damaging 
effects by increasing the expression of profibrotic pathways 
and molecules, such as transforming growth factor-β.32 
  Additionally, the receptor may amplify renin-induced angio-
tensin II-dependent effects. Plasma renin activity is blocked 
only by aliskiren. Elevated baseline plasma renin activity in 
untreated patients has been associated with end-organ damage, 
such as left ventricular hypertrophy and renal dysfunction,33,34 
probably due to high angiotensin II levels. Renin inhibition 
with aliskiren therefore offers the chance of enhanced RAAS 
suppression and improved end-organ protection either alone 
or in combination with other antihypertensive drugs.35
Aliskiren is poorly absorbed, with an absolute oral bio-
availability of 2.5% with maximum plasma aliskiren concen-
trations reached within 1–3 hours of oral administration.36,37–39 
Although food has a big effect on the pharmacokinetics of 
aliskiren, the resulting decreases in aliskiren exposure are not 
considered clinically relevant.40 Steady-state plasma concen-
trations are reached 5–8 days after once-daily oral administra-
tion of aliskiren.36,41 The half-life of oral aliskiren is around 
24 hours;40 it is approximately 50% protein bound in human 
plasma, and protein binding is independent of aliskiren 
plasma concentration.41 Hepatic and renal metabolism are 
not major routes of aliskiren elimination.40,41 Following a 
single oral 300 mg dose, aliskiren has an elimination half-
life of 40 hours in healthy volunteers.42 Excretion is almost 
completely by the fecal route (91.5%), with 77.5% of the 
dose excreted as unchanged drug.43 The pharmacokinetics of 
aliskiren are not affected by sex,36,41 body mass index,36,41 or 
race and are similar in Chinese, Japanese, and Caucasian44–46 
patients. The pharmacokinetics of aliskiren in patients with 
hepatic impairment, mild to severe renal disease,36,41 or type 
2 diabetes42 are no different from those of healthy volunteers. 
Thus, initial dosage adjustments are not necessary in patients 
with renal or hepatic impairment.36,41
Aliskiren has a low potential for clinically relevant inter-
actions with other drugs.40,41 However, coadministration of 
aliskiren with irbesartan decreased the aliskiren maximum 
concentration by 50% after multiple dosing.36,41 The expo-
sure to aliskiren was not altered by coadministration of 
furosemide.47 However, furosemide decreased by 28% and 
49% with concomitant aliskiren administration. Although 
the clinical significance of this is unclear, the effects of 
furosemide should be monitored.41 When aliskiren was 
coadministered with rifampicin, the latter reduced aliskiren 
concentration by 39%.48 Coadministration of aliskiren with 
potent P-glycoprotein inhibitors (cyclosporine, quinidine, 
and verapamil) is virtually contraindicated because aliskiren 
plasma concentrations significantly increase, and aliskiren 
and moderate P-glycoprotein inhibitors (ketoconazole, itra-
conazole, clarithromycin, telithromycin, erythromycin, and 
amiodarone) should be coadministered with caution. Grape-
fruit juice should not be taken together with aliskiren.41
One concern is the potential adverse effect of high circu-
lating renin concentrations after aliskiren therapy. As men-
tioned previously, aliskiren binds to the active site of renin, 
reducing its activity (plasma renin activity) and angiotensin II 
production. Diminished angiotensin II levels stimulate renin 
secretion (plasma renin concentration). The potential nega-
tive consequence of high renin concentration is that renin may 
bind to a renin receptor and trigger yet unknown events.49 
However, an important contributor to the exaggerated renin 
response is interference by the renin inhibitor in the renin 
assay causing overestimation of the renin concentration.50 
Thus, this renin response may not actually represent an 
increase in enzymatically active renin molecules in plasma. 
The question of whether this increase in renin concentra-
tion has any effect remains unanswered. Although aliskiren 
lowers plasma renin activity, renin concentration rises, and 
ACEIs and ARBs increase both.51,52 As mentioned previously, 
high levels of renin can activate the prorenin/renin receptor, International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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which aside from activating prorenin, can possibly initiate 
ERK1/2 signaling and transform growth factor-β activation 
and other potentially serious complications.25,53 However, 
ACEIs and ARBs also leave these issues unresolved with 
a partial inhibition of angiotensin II concentration, despite 
good blood pressure control. Some authors have argued 
against renin inhibition, because plasma renin concentra-
tions attained after aliskiren are higher than those obtained 
after ARBs.54 However, in some studies in mice, ARBs have 
caused higher plasma renin concentrations than aliskiren. 
This discrepancy could partly be due to the method employed 
to measure renin concentrations in mice and humans.55 
Plasma renin activity is blocked only by aliskiren. 
Elevated baseline plasma renin activity in untreated patients 
has been associated with end-organ damage, such as left 
ventricular hypertrophy and renal dysfunction,56,57 probably 
due to high angiotensin II levels.58 Renin inhibition with 
aliskiren therefore offers the chance of enhanced RAAS 
suppression and improved end-organ protection, either alone 
or in combination with other antihypertensive drugs.25,59 The 
kidney is an important site of the uptake of renin inhibitors, 
and aliskiren has been found in renal glomeruli, renal arter-
ies, and capillaries.60,61 Aliskiren may act directly on the 
renin-secreting juxtaglomerular cell to influence prorenin 
processing and renin release.50
Efficacy studies and organ 
protection
Efficacy studies
The therapeutic efficacy of aliskiren will be outlined in this 
section at a dosage of 150 mg/day or 300 mg/day alone 
and compared with placebo and ACEIs or ARBs and/or 
combined with hydrochlorothiazide, valsartan, valsartan 
plus hydrochlorothiazide, amlodipine, amlodipine plus 
hydrochlorothiazide, ramipril, and atenolol. In general, adult 
patients were enrolled in these trials with diastolic blood pres-
sures .90–95 mm Hg and ,110 mm Hg or mean systolic 
blood pressures between .160 mm Hg and ,200 mm Hg. 
Patients with secondary hypertension, severe cardiovascular 
disease, uncontrolled diabetes mellitus, and hepatic or renal 
disease were excluded from most studies. A concise, thor-
ough, updated review has recently been published.62
Monotherapy
In the 8-week, placebo-controlled trials, monotherapy with 
aliskiren 150 mg/day or 300 mg/day reduced baseline sys-
tolic and diastolic blood pressure to a significantly greater 
extent than placebo in patients with stage 1 to stage 2 
hypertension.63–67 The antihypertensive efficacy of aliskiren 
monotherapy was also demonstrated in subgroups of patients, 
including diabetic and obese patients and those with meta-
bolic syndrome.68
Comparisons with other agents
Across a number of trials in patients with hypertension, 
aliskiren monotherapy was generally as effective as hydro-
chlorothiazide, ramipril, lisinopril, irbesartan, atenolol, 
valsartan, and losartan at reducing blood pressure in short-
term studies. In long-lasting, double-blind trials, aliskiren-
based therapy was at least as effective as ramipril-based 
therapy69 and more effective than hydrochlorothiazide-based 
therapy.70
Aliskiren 150–300 mg/day was more effective than 
irbesartan 150–300 mg/day71 and generally as effective as 
valsartan 160–320 mg/day72 and losartan 100 mg/day73 in 
lowering blood pressure. Aliskiren did not differ significantly 
from atenolol in lowering systolic blood pressure in a study 
in which patients received aliskiren 150 mg/day or atenolol 
50 mg/day for 6 weeks followed by 6 weeks on double the 
initial dose of the agents.74 However, reductions in diastolic 
blood pressure were significantly greater with atenolol than 
with aliskiren at both 6 weeks and 12 weeks.
Combination therapy
The efficacy75–77 of aliskiren in combination with other 
antihypertensives has been evaluated in randomized, double-
blind or open-label, multicentre trials in which aliskiren 
150–300 mg/day was administered in combination with 
hydrochlorothiazide, valsartan, valsartan plus hydrochloro-
thiazide, amlodipine, amlodipine plus hydrochlorothiazide, 
ramipril, and atenolol.
In patients with stage 1 to stage 2 hypertension, combined 
strategies of aliskiren plus hydrochlorothiazide were more 
effective than aliskiren, hydrochlorothiazide, or ramipril 
monotherapies, and at least as effective as amlodipine, in 
reducing blood pressure in patients with stage 2 hyperten-
sion, including patients with diabetes, patients with obesity, 
patients with metabolic syndrome, African American patients, 
and aged patients.78–83 Patients who received aliskiren plus 
valsartan had significantly greater blood pressure reductions 
than with either an individual component or placebo.84 The 
antihypertensive effect of the combination of aliskiren plus 
valsartan was similar in patients with or without diabetes.36 
The antihypertensive effects of the aliskiren plus valsartan 
combination were diminished in African American patients, 
as was the case with ACEIs, ARBs, and atenolol.36International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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Aliskiren in combination with amlodipine was effective in 
lowering BP in patients with stage 1 to stage 2 hypertension.62 
First-line therapy with combination aliskiren 150 mg/day 
or 300 mg/day plus amlodipine 5–10 mg/day provided 
significantly greater control than the respective monothera-
pies in patients with stage 2 hypertension.85 Combination 
therapy was also more effective than amlodipine monotherapy 
as first-line therapy in African-American patients with stage 
2 hypertension.86 This was also observed irrespective of 
age, sex, and the presence of diabetes or obesity.62 Finally, 
aliskiren in combination with ramipril led to a significantly 
greater reduction in blood pressure than with each indi-
vidual component in hypertensive patients with type 1 
or 2   diabetes.84 In a study combining aliskiren 150 mg/day 
with atenolol 50 mg/day, there were greater reductions 
in blood pressure than with aliskiren monotherapy after 
12 weeks’ treatment.87
Safety and tolerability
Aliskiren was generally well tolerated at doses of 150 or 
300 mg/day62 and resulted in an incidence of adverse events 
similar to placebo.41 Adverse events, including uncontrolled 
hypertension (2.2%),36 have generally been mild and have 
infrequently led to discontinuation of therapy.41 The most 
common adverse events reported are headache (5.8%), 
nasopharyngitis (2.6%), and diarrhea (1.4%).62 Aliskiren was 
also associated with a few cases of cough (1.1%), although, 
compared with ACEIs, the rate of cough was approximately 
one-third to one-half that reported with ramipril or lisinopril.36 
Although aliskiren has rarely been associated with changes 
in laboratory parameters, it is still prudent to monitor hemo-
globin concentration and serum levels of creatinine, urea, 
potassium, uric acid, and creatine kinase.36,41,62
Organ protection
In respect of organ protection, although blood pressure-
lowering effects with aliskiren are well established, its 
effects on cardiovascular morbidity and mortality are yet to 
be determined. A clinical program is under way to assess the 
potential benefits of aliskiren in clinical outcomes. Details 
on studies on the renoprotective and cardioprotective effects 
of aliskiren in hypertensive, diabetic subjects with nephropa-
thy (Aliskiren in the Evaluation of Proteinuria in Diabetes 
[AVOID]),88 reduced left ventricular hypertrophy (Aliskiren 
in Left Ventricular Hypertrophy [ALLAY]),89 symptomatic 
heart failure (Aliskiren Observation in Heart Failure Treat-
ment [ALOFT]),90 acute coronary symptoms,91 and postmyo-
cardial infarction with low ejection fraction (Aliskiren Study 
in Post-MI Patients to Reduce Remodelling [ASPIRE])92 are 
available in the literature.
Aliskiren-based therapy demonstrated positive effects 
on the markers of cardiovascular and renal damage in 
hypertensive patients with type 2 diabetes and nephropa-
thy, reducing proteinuria independently of blood pressure 
control88 in patients with reduced left ventricular hyper-
trophy89 or in those with symptomatic heart failure and 
reduced plasma N-terminal probrain natriuretic peptide.90 
However, aliskiren therapy did not have a beneficial effect 
on left ventricular remodeling after myocardial infraction.92 
Add-on aliskiren 300 mg/day had no significant beneficial 
effect on left ventricular end-systolic volume compared with 
placebo (ASPIRE).92 Further studies are currently under way 
to evaluate the effect of aliskiren on the following clini-
cal outcomes: reduction of cardiovascular death and heart 
failure rehospitalization events within 6 months in patients 
with congestive heart failure hospitalized for an episode of 
acute decompensated heart failure (Aliskiren Trial on Acute 
Heart Failure Outcomes [ASTRONAUT]),93 morbidity and 
mortality in patients with type 2 diabetes and pre-existing 
cardiovascular disease and/or kidney disease (Aliskiren Trial 
in Type 2 Diabetes Using Cardio-renal Disease Endpoints 
[ALTITUDE]),94 and morbidity and mortality in patients with 
chronic heart failure (Aliskiren Trial to Minimize   Outcomes 
in Patients with Heart Failure [ATMOSPHERE]).95 The 
potential benefit of aliskiren on long-term outcomes is cur-
rently being evaluated as part of the larger ASPIRE HIGHER 
program (n = 35,000).
Patient-focused perspectives
Aliskiren can be employed in patients with hypertension, and 
in particular in subjects with proteinuria. Despite the possibil-
ity of an occasional forgotten dose (missing dose), it exerts 
protection beyond 24 hours due to its long half-life. This 
feature is not associated with a higher risk of hypotension.41 
An important advantage is that aliskiren does not need to 
be adjusted in patients with hepatic or renal disease. As an 
antihypertensive drug, aliskiren is equivalent to any other 
drug and may not present major differences in blood pressure 
control when used as monotherapy, particularly at 300 mg/day. 
However, in hypertensive patients with proteinuria, it may 
present some advantages. It can be used alone or in combina-
tion with other drugs to achieve low protein urinary excretion. 
Although aliskiren does not present a renal route of elimi-
nation and would potentially be useful at any stage of renal 
disease, there is still not enough information to recommend 
its use in chronic renal failure stages 4 or 5. Patients with International Journal of Nephrology and Renovascular Disease 2011:4 submit your manuscript | www.dovepress.com
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  renin-dependent hypertension are a target population. In 
these cases, potassium levels must be monitored periodically. 
  Diabetics appear to benefit from aliskiren, independently 
of being normotensive or hypertensive, normoalbuminuric, 
microalbuminuric, or proteinuric. Aliskiren can block prorenin 
activity, which is increased in diabetic subjects and associated 
with inflammatory processes systemically. Although plasma 
renin activity is suppressed by aliskiren, plasma renin concen-
tration remains high, and the eventual consequences of this 
phenomenon are still unknown in the adult population.25
In patients with primary or secondary glomerulopathies, 
such as lupus nephritis, in which immunosuppression is 
the mainstay of treatment, once the acute process has been 
approached and renal function stabilized, aliskiren could be 
used alone or in combination with ARBs, ACEIs, or other anti-
hypertensive drugs to inhibit angiotensin II-induced inflamma-
tory processes (vascular remodeling, tissue fibrosis) to decrease 
proteinuria and the maintenance dose of immunosuppressants. 
In addition, in patients with glomerulopathies and moderate 
degrees of proteinuria (eg, immunoglobulin A, focal and seg-
mental glomerulosclerosis), a first attempt to decrease protein 
excretion avoiding the use of immunosuppression could be the 
employment of aliskiren alone or in combination with other 
antihypertensive drugs, particularly ACEIs or ARBs.
Conclusion
Patients who could benefit most from aliskiren alone or 
in combination include glomerular proteinuric subjects 
and patients with moderate to high cardiovascular risk. 
As high plasma renin activity is regarded as a risk factor 
for myocardial infarction in untreated hypertensive and 
normotensive patients, this population could benefit from 
aliskiren   prescription.48 Diuretics, β-blockers, and calcium 
channel blockers appear to be good options for combinations. 
Associations with ACEIs or ARBs should be preferentially 
reserved for proteinuric patients and, in this case, combina-
tions should be approached in a step-by-step fashion, increas-
ing doses gradually. Severe vasodilatation must be avoided, 
salt-free diets must be encouraged, and serum creatinine 
and potassium levels must be followed initially until the full 
designed dose is achieved. Proteinuria and blood pressure 
are the main goals to control.
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